Even more support with 3-times-a-week COPAXONE® (glatiramer acetate injection) 40 mg                 There are a number of reasons why you and so many others in the MS community have put your trust in COPAXONE®, the #1 prescribed brand for relapsing MS in the US.1* Now there are even more reasons! With the availability of new 3-times-a-week COPAXONE® 40 mg, you can have proven effectiveness, a demonstrated safety and tolerability profile, plus the freedom to dose 3 times a week.2** On top of all that, there are now newly enhanced offerings available from Shared Solutions®.     Even more support...     COPAXONE iTracker® for your smartphone or tablet and the brand new COPAXONE webTracker on your desktop have been updated for use with 3-times-a-week COPAXONE® 40 mg     Printed Planner and Reminder Stickers to keep on hand and stay on track     Free in-home refresher training to create a customized injection plan and to help you transition to the new 3-times-a-week injection schedule     Through COPAXONE Co-pay Solutions®, eligible patients taking 3-times-a-week COPAXONE® 40 mg could lower their co-pay to $0 per month out of pocket†     24/7 phone support by MS-certified nurses and ongoing nurse support outreach calls     One-on-one support from MS Peers‡ for added encouragement and inspiration     Track, record, personalize, and organize no matter where you are with the COPAXONE iTracker® and webTracker.               And even more freedom to...   Be Bold. Take control of your relapsing MS by choosing a therapy with proven results.   Be True. Make a commitment—and stay the course with a therapy you trust.   Be You. Arrange your treatment around your life—not your life around your treatment.     Talk to your doctor today about all the reasons to get started on new 3-times-a-week COPAXONE® 40 mg       COPAXONE® is indicated for the treatment of patients with relapsing forms of multiple sclerosis.   Important Safety Information   Do not take COPAXONE® if you are allergic to glatiramer acetate or mannitol.   Some patients report a short-term reaction right after injecting COPAXONE®. This reaction can involve flushing (feeling of warmth and/or redness), chest tightness or pain with heart palpitations, anxiety, and trouble breathing. These symptoms generally appear within minutes of an injection, last about 15 minutes, and do not require specific treatment. During the postmarketing period, there have been reports of patients with similar symptoms who received emergency medical care. If symptoms become severe, call the emergency phone number in your area. Call your doctor right away if you develop hives, skin rash with irritation, dizziness, sweating, chest pain, trouble breathing, or severe pain at the injection site. If any of the above occurs, do not give yourself any more injections until your doctor tells you to begin again.   Chest pain may occur either as part of the immediate postinjection reaction or on its own. This pain should only last a few minutes. You may experience more than one such episode, usually beginning at least one month after starting treatment. Tell your doctor if you experience chest pain that lasts for a long time or feels very intense.   A permanent indentation under the skin (lipoatrophy or, rarely, necrosis) at the injection site may occur, due to local destruction of fat tissue. Be sure to follow proper injection technique and inform your doctor of any skin changes.   The most common side effects in studies of COPAXONE® are redness, pain, swelling, itching, or a lump at the site of injection, flushing, rash, shortness of breath, and chest pain. These are not all of the possible side effects of COPAXONE®. For a complete list, ask your doctor or pharmacist. Tell your doctor about any side effects you have while taking COPAXONE®.   You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.   Please see full Prescribing Information.       *Based on total number of prescriptions for relapsing forms of MS (IMS National Rx Audit, September 2013).   **With injections at least 48 hours apart.   †Applies only to 3-times-a-week COPAXONE® 40 mg. Certain limits and restrictions apply.   Terms and Conditions include: COPAXONE Co-pay Solutions® is open to both new and existing patients who are residents of the US or Puerto Rico and who have commercial prescription insurance coverage for COPAXONE® 40 mg. The offer is not valid for uninsured patients or patients covered in whole or in part by Medicaid, Medicare, TRICARE, or any other federal or state government pharmaceutical assistance plan or program (regardless of whether a specific prescription is covered), or by private health benefit programs that reimburse for the entire cost of prescription drugs. Use of this offer must be consistent with the terms of any drug benefit provided by a health insurer, health plan, or private third-party payor. This offer is void where prohibited by law, taxed, or restricted. No additional purchase is required. This offer is valid only at participating pharmacies and may be changed or discontinued at any time without notice. This program is not health insurance.   ‡Peers with relapsing forms of MS.   References: 1. IMS Health National Prescription Audit, September 2013. Data proprietary to IMS Health. 2. COPAXONE® (glatiramer acetate injection) prescribing information. Teva Neuroscience, Inc.   Privacy Policy | One-click Unsubscribe | Terms of Use     COPAXONE® is a registered trademark of Teva Pharmaceutical Industries Ltd. Shared Solutions® is a registered service mark of Teva Neuroscience, Inc. COPAXONE iTracker® is a registered trademark of Teva Pharmaceutical lndustries Ltd. COPAXONE CO-PAY SOLUTIONS® is a registered trademark of Teva Pharmaceutical lndustries Ltd. © 2014 Teva Neuroscience, Inc. COP-41443 Teva Neuroscience, Inc., COPAXONE® Marketing, 11100 Nall Avenue, Overland Park, KS 66211